EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 21-Sep-2025 11:11 ET (21-Sep-2025 15:11 GMT/UTC)

8-Sep-2025

Cancer cells can use backup routes to fuel their growth

Van Andel Research Institute
Peer-Reviewed Publication

A new study by Van Andel Institute scientists suggest that the routes cancer cells use to process different nutrients deeply influence cell behavior. They discovered an alternate, or non-canonical, path by which cancer cells convert a ketone called β-hydroxybutyrate (β-OHB) into acetyl-CoA, an essential metabolic building block for fatty acids and cholesterol that supports cell proliferation. The findings, published today in the journal Nature Metabolism, could reshape how the relationship between diet and cancer is viewed.

Journal: Nature Metabolism
Funder: NIH/National Cancer Institute, NIH/National Cancer Institute, NIH/National Institute of Allergy and Infectious Diseases, Van Andel Institute Metabolism & Nutrition (MeNu) Program, Canadian Institutes of Health Research

8-Sep-2025

Tarlatamab with anti-PD-L1 as first-line maintenance after chemo-immunotherapy for ES-SCLC demonstrates acceptable safety profile and unprecedented overall survival

International Association for the Study of Lung Cancer
Reports and Proceedings

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

8-Sep-2025

Moffitt develops first genetically engineered cancer model in naked mole rats

H. Lee Moffitt Cancer Center & Research Institute
Peer-Reviewed Publication

Researchers at Moffitt Cancer Center have created the first genetically engineered model of lung cancer in naked mole rats, a species long thought to be resistant to cancer. The findings, published in Cancer Discovery, shed light on how cancer begins in this unusual rodent and may reveal new parallels to tumor development in humans.

Journal: Cancer Discovery
Funder: NIH/National Institutes of Health

8-Sep-2025

First-ever clinical trial demonstrates safety, molecular readout and promise of pre- and post-surgery immunotherapy combination for patients with operable mesothelioma

Johns Hopkins Medicine
Peer-Reviewed Publication

A novel treatment approach using combination immunotherapy before and after surgery shows promise for patients with operable mesothelioma, according to a new study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

Journal: Nature Medicine
Funder: Department of Defense Congressionally Directed Medical Research Program, Johns Hopkins Kimmel Cancer Center NCI, U.S. Food and Drug Administration, NIH/National Institutes of Health, Bloomberg~Kimmel Institute for Cancer Immunotherapy, ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center, Robyn Adler Fellowship Award, Commonwealth Foundation, Mark Foundation For Cancer Research, Florence Lomax Eley Fund

8-Sep-2025

‘Rogue’ DNA rings reveal earliest clues to deadly brain cancer’s growth

Queen Mary University of London
Peer-Reviewed Publication

An international team of scientists has revealed how rogue rings of DNA that float outside of our chromosomes – known as extrachromosomal DNA, or ecDNA – can drive the growth of a large proportion of glioblastomas, the most common and aggressive adult brain cancer. The discovery could open the door to much-needed new approaches to diagnose glioblastoma early, track its progress and treat it more effectively.

Journal: Cancer Discovery
Funder: Francis Crick Institute, Cancer Research UK, NIH/National Cancer Institute

8-Sep-2025

Clinical study deepens understanding of mesothelioma and opens the door to potential treatment options

Georgetown University Medical Center
Peer-Reviewed Publication

People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the role of surgery for this difficult to treat cancer.

Journal: Nature Medicine
Funder: The trial was sponsored by Bristol Myers Squibb.

8-Sep-2025

High-grade serous carcinomas identified in cervical biopsies: A clinicopathologic study supporting the exclusion of cervical serous carcinoma from World Health Organization classification

Xia & He Publishing Inc.
Peer-Reviewed Publication

High-grade serous carcinoma is a rare diagnosis in cervical biopsies. Cervical serous carcinoma is no longer recognized as a primary cervical tumor in the 2020 World Health Organization classification. This study aimed to characterize the clinicopathologic, immunohistochemical, and molecular features of high-grade serous carcinoma identified in cervical or endocervical biopsies, to assess tumor origin and ensure accurate classification.

Journal: Journal of Clinical and Translational Pathology

8-Sep-2025

New study and major data updates expand the Kids First data ecosystem

Gabriella Miller Kids First Data Resource Center
Business Announcement

The Gabriella Miller Kids First Pediatric Research Program (Kids First) has released its 36th study and introduced significant new data updates to two existing studies, further advancing efforts to uncover the genetic foundations of childhood cancers and congenital conditions. This brings the total data files available at the Kids First Data Resource Center (Kids First DRC) to more than 110,000.

8-Sep-2025

Frailty fuels gut imbalance and post-surgery gastrointestinal risks

Fujita Health University
Peer-Reviewed Publication

A new study reveals that frailty-associated gut dysbiosis significantly elevates the risk of gastrointestinal complications following intracorporeal urinary diversion for bladder cancer. Despite short-term antibiotic prophylaxis, residual intra-abdominal bacteria and fungi—particularly Enterococcus and Enterobacter—were strongly associated with postoperative ileus and infections. The findings underscore frailty as a key determinant of surgical outcomes and point toward microbiota-based management strategies to improve recovery and reduce complications.

Journal: Scientific Reports

8-Sep-2025

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

International Association for the Study of Lung Cancer
Reports and Proceedings

BMS-986504, a first-in-class methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) targeting agent, showed promising antitumor activity in heavily pretreated patients with MTAP-deleted non-small cell lung cancer (NSCLC), according to results from the Phase 1CA240-0007 trial presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).